Under the terms of the agreement, Nona Biosciences will receive an upfront payment of $19 million, with potential milestone payments of up to $585 million.
AstraZeneca and Nona Biosciences sign global license and option agreement to develop monoclonal antibodies for targeted tumor therapy
Leave a comment
